Vector BioPharma and the Instituto de Biologia Experimental e Tecnológica (iBET) have agreed a multi-phase collaboration to advance the technical development of Vector’s gene delivery platform.  Vector BioPharma’s gene delivery platform combines high-capacity virus-like particles with exogenous, high-avidity adapter proteins.  Lorenz Mayr, CEO at Vector BioPharma, said: “Collaboration with industry-leading R&D institutions and researchers in […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!